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Abstract
Background: Antiretroviral treatment (ART) has contributed to increased life expectancy of HIV-1 infected children. In
developed countries, an increasing number of children reaching adulthood are transferred to adult units. The objectives
were to describe the demographic and clinical features, ART history, antiviral drug resistance and drug susceptibility in HIV-1
perinatally infected adolescents transferred to adult care units in Spain from the Madrid Cohort of HIV-1 infected children.
Methods: Clinical, virological and immunological features of HIV-1 vertically infected patients in the Madrid Cohort of HIV-
infected children were analyzed at the time of transfer. Pol sequences from each patient were recovered before transfer.
Resistance mutations according to the InternationaI AIDS Society 2011 list were identified and interpreted using the
Stanford algorithm. Results were compared to the non-transferred HIV-1 infected pediatric cohort from Madrid.
Results: One hundred twelve infected patients were transferred to adult units between 1997 and 2011. They were mainly
perinatally infected (93.7%), with a mean nadir CD4+-T-cells count of 10% and presented moderate or severe clinical
symptoms (75%). By the time of transfer, the mean age was 18.9 years, the mean CD4+T-cells count was 627.5 cells/ml,
64.2% presented more than 350 CD4+T-cells/ml and 47.3% had #200 RNA-copies/ml. Most (97.3%) were ART experienced
receiving Highly Active ART (HAART) (84.8%). Resistance prevalence among pretreated was 50.9%, 76.9% and 36.5% for
Protease Inhibitors (PI), Nucleoside Reverse Transcriptase Inhibitors (NRTI) and Non-NRTI (NNRTI), respectively. Resistance
mutations were significantly higher among transferred patients compared to non-transferred for the PI+NRTI combination
(19% vs. 8.4%). Triple resistance was similar to non-transferred pediatric patients (17.3% vs. 17.6%).
Conclusion: Despite a good immunological and virological control before transfer, we found high levels of resistance to PI,
NRTI and triple drug resistance in HIV-1 infected adolescents transferred to adult units.
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Introduction
By the end of 2010, of the 34 million people living with human
immunodeficiency virus (HIV), there were 3.4 million children
below the age of 15 years [1]. During 2010, 390.000 children were
infected with HIV and 250.000 died from AIDS related causes [1].
In Western Europe and North America the HIV epidemic has
remained stable since 2004. In 2010, one million infected
individuals lived in Western and Central Europe, including
6,000 infected children [1]. In the WHO European Region of
the 646 children who acquired the HIV infection through mother-
to-child transmission (MTCT) [2], 19% of them originated from
countries with generalized epidemics (in sub-Saharan Africa, the
Caribbean and Asia).
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Due to the expanded access to highly active antiretroviral
treatment (HAART) and prevention efforts in HIV testing,
prenatal care, formula feeding, elective Caesarean and pregnancy
monitoring [3–5], few children were newly infected with HIV
(,500) or died from AIDS-related illnesses (,500) in Western
Europe in 2010. This reflects the extensive provision of services
that can prevent MTCT of HIV [6,7]. Despite the success of
preventive measures, MTCT still occurs in high-income countries
[8–10] mainly due to infected immigrants from countries with a
high HIV prevalence and within social compartments that refuse
pregnancy monitoring and HIV testing. A total of 80.827 cases of
AIDS had been declared in Spain [11] by the end of 2010; these
958 were children infected through MTCT. During 2010, a total
of 2907 new HIV infections cases were notified in Spain, twelve of
them caused by MTCT (0.4%) mainly (8/12 cases) among foreign
patients. In the region of Madrid, a total of 805 HIV infection
cases were reported in 2010, 2 of them caused by MTCT [11].
In developed settings with access to HAART, perinatally
acquired HIV-1 infection has become a chronic disease of
childhood with increasing numbers of adolescents surviving to
adulthood and transitioning from pediatric to adult services.
Perinatally infected adolescents have been heavily pretreated, have
a long history of treatment with many switches and variable levels
of adherence to the treatment have been reported. Sub-optimal
treatments and non-complete compliance can increase the
prevalence of drug resistance mutations in HIV thus, compromis-
ing the success of present and future treatment options.
Successful transition to adult services has become a necessity in
these heavily pretreated patients. Teenagers growing up with
HIV/AIDS have common problems related to social difficulties
and to side-effects of HIV and HAART which play an impact on
their growth and development. The objectives of this study were to
describe the demographic and clinical features, antiretroviral
therapy (ART) history, antiviral drug resistance and susceptibility
to drugs in HIV-1 perinatally infected adolescents transferred to
adult units in Spain from the Madrid Cohort of HIV-1 infected
children.
Patients and Methods
Study Population
Since the beginning of the HIV epidemic in Spain, a total of
534 patients have been registered in the Madrid cohort of HIV-
infected children established in 2003. By the end of December
2011, 175 of them still remained under clinical follow-up in
pediatric units, 112 had been transferred to adult units, 62 had
been lost to follow-up and 185 had died. In this study we selected
the 112 patients from the cohort that had reached adolescence and
been transferred to adult units in 8 public hospitals from 1997 to
December 2011. Clinical and epidemiological features of all
transferred patients were recorded from the database of the
cohort.
An additional cohort of HIV-1 infected patients was used to
compare results on drug resistance and drug sensitivity. The
selected cohort consisted of the HIV Madrid cohort of non-
transferred perinatally infected patients previously described
[12,13].
This study was part of a project approved by the review board
of the Hospital Universitario Ramo´n y Cajal Clinical Research
Ethical Committee. It was designed to protect the right of all
subjects involved under the appropriate local regulations. To
maintain subject confidentiality, a unique number was assigned to
each specimen, and written consent obtained for each patient by
clinicians.
Drug Resistance Analysis
For the drug resistance study, we selected those transferred
patients according to pol sequence, genotypic resistance profile or
sample availability by December 2011. Most genetic sequences
and genotypic resistance profiles were previously reported [12,13]
or recovered from clinical routine drug-resistance tests performed
in hospitals where patients were or had been under follow-up.
When more than one sample was available per patient, we selected
the closest and previous to the time of transference to adult units
among transferred subjects and the most recent for non-
transferred patients.
Previously reported genotypes were performed from infected
samples (immortalized DNA, plasma or peripheral blood mono-
nuclear cells, PBMCs) kindly provided by the HIV BioBank
integrated in the Spanish AIDS Research Network (RIS) [14,15].
Samples from patients were processed following current proce-
dures and frozen immediately after their reception. Sample
collection, processing and storing were performed under interna-
tional guidelines for biological storing and under supervision of a
Scientific and Ethical Committee. HIV-1 subtyping of new
sequences was performed by phylogenetic analysis (phy) as
previously described [13].
The prevalence of transmitted drug resistance among naı¨ve
patients was defined according to the list of mutations for
Transmitted Drug Resistances (TDR) surveillance, as recom-
mended by the WHO [16] using the Calibrated Population
Resistance tool [17]. Drug-resistance mutations (DRM) in
pretreated patients were defined by the International AIDS
Society-USA list (IAS) [18]. Drug susceptibility was estimated for
each available antiretroviral according to the HIVdb Interpreta-
tion Algorithm version 6.0.11 (Stanford University, Palo Alto, CA,
USA) [19].
Statistical Analysis
Prevalence was expressed in percentage with a 95% confidence
interval (CI). CI tests were performed with Epidat 3.1 (Pan
American Health Organization). Statistical significance was set at
p,0.05.
Results
Baseline Features of the Transferred Population
A total of 112 patients of the Madrid cohort of HIV-infected
children transferred from pediatric services to adult units in
different hospitals in Madrid between 1997 and December 2011
were selected for this study. Baseline characteristics of the non-
transferred (n = 131), total transferred (n = 112), and transferred
patients with available genotypic profile (n = 63) are summarized
in Table 1. All transferred patients were HIV-1 diagnosed at
childhood (mean 2 years of age), the majority were born in Spain
(91.9%) and mainly infected through MTCT (93.7%). Only a few
(12.5%) were adopted. Most (81.3%) were diagnosed along the
1985–1994 period. The median duration of follow-up was 13.2
(Standard Deviation, SD 5.2), 15.6 (SD 4.5), and 16.7 (SD 3.6)
years for non-transferred, transferred (n = 112) and transferred
with available resistance genotypic profile, respectively.
Advanced stages of immunosuppression were observed as a
result of the long term infection and scarce effective antiretroviral
availability before 1996. Over two thirds of transferred patients
reached less than 15% CD4+ cell counts and half (57.1%) reached
,200 cells/mm3. The mean nadir CD4+ T-cells count was 10%.
Monotherapy was the first ARV treatment in 59.8%, mainly with
AZT (79.1%), 23.2% started with combined therapy (including
AZT backbone in 88.4% of them) and only 14.3% with HAART.
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Table 1. Baseline characteristics of the non-transferred, transferred and transferred with available genotypic profile patients.
Features Non-transferred n=131 Transferred n=112 Transferred with genotype* n=63
[n (%)] [n (%)] [n (%)]
Adopted 31 (23.7) 14 (12.5) 8 (12.7)
Female gender 76 (58) 60 (53.6) 34 (54)
Median age until diagnosis (years) 0.5 2 1.4
Non-B variants prevalence (%) 11.6 – 1.9
Demographics
Caucasian 100 (76.3) 98 (87.5) 59 (93.6)
Hispanic 6 (4.6) 4 (3.5) 2 (3.2)
Romani 4 (3.1) 3 (2.7) 1 (1.6)
African** 18 (13.7) 2 (1.8) –
Other 2 (1.5) 2 (1.8) 1 (1.6)
Unknown 1 (0.8) 3 (2.7) –
Origina
Europe 112 (85.5) 105 (93.7) 61 (96.8)
North America 1 (0.8) – –
South and Central America 8 (6.1) 5 (4.5) 2 (3.2)
North Africa 2 (1.5) – –
Sub-Saharan Africa 7 (5.3) 2 (1.8) –
Asia 1 (0.8) – –
Year of HIV diagnosis
1985–1989** 1 (0.8) 31 (27.7) 16 (25.4)
1990–1994** 37 (28.2) 60 (53.6) 39 (61.9)
1995–1999** 54 (41.2) 18 (16) 7 (11.1)
2000–2004** 28 (21.4) 3 (2.7) 1 (1.6)
2005–2009 10 (7.6) – –
Unknown 1 (0.8) – –
Route of infection
Perinatally 127 (96.9) 105 (93.7) 61 (96.8)
Transfusion 3 (2.3) 5 (4.5) 2 (3.2)
Unknown 1 (0.8) 2 (1.8) –
Year of transfer
1997–1999 – 3 (2.7) –
2000–2002 – 9 (8) 1 (1.6)
2003–2005 – 27 (24.1) 13 (20.7)
2006–2008 – 33 (29.5) 21 (33.3)
2009–2011 – 40 (35.7) 28 (44.4)
Nadir CD4 count achieved Mean 10% Mean 11%
,15% 67 (51.1) 75 (67) 43 (68.3)
15–24% 42 (32.1) 24 (21.4) 13 (20.6)
$25% 19 (14.5) 13 (11.6) 7 (11.1)
Unknown 3 (2.3) – –
Nadir CD4 count achieved (cells/mm3)
,200** 35 (26.7) 64 (57.1) 31 (52.4)
200–499 63 (48.1) 37 (33) 26 (38.1)
$500** 30 (22.9) 11 (9.9) 6 (9.5)
Unknown 3 (2.3) – –
aOrigin of patients by country: Spain (n = 103), Portugal (n = 1), Romania (n = 1), Honduras (n = 2), Argentina (n = 1), Mexico (n = 1), Peru (n = 1), Cape Verde (n = 1),
Equatorial Guinea (n = 1).
*Transferred to adult units with available resistance genotyping profile.
**Statistical differences (p,0.05) have been found between transferred and non-transferred patients for these features. HIV-1 non-B variants include HIV-1 non-B
subtypes and recombinants.
doi:10.1371/journal.pone.0052155.t001
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In the transferred cohort compared to the non-transferred, a
statistical significant lower number of African patients were found
(1.8% vs. 13.7%, p,0.05), a significant higher number of children
reached nadir CD4-Tcell values below 200 (57.1 vs. 26.7, p,0.05)
and a lower number of patients achieved CD4 T-cells over 500
(9.9% vs. 22.9%, p,0.05). No statistical differences were found in
the baseline studied characteristics between transferred patients
with and without available genotype (Table 1).
Features of the Population at the Time of Transfer
Characteristics of the study population at the time of transfer to
adult units are shown in Table 2. By the time of transfer, the
mean age was 18.9 years and the mean CD4+T-cells count 627.5
cells/ml. 5.4% presented less than 15% CD4+T-cells, 66% more
than 25% and 55.3% more than 500 CD4+ cells/ml counts.
Nearly all (98.2%) had presented signs and symptoms of AIDS
according to CDC classification [20], which were severe in 34.8%
of cases. Immunological status at the time of the transfer revealed
an immunologically severe suppression in 66.9% (CDC stage 3).
Among the 102 patients with available viral load data, 56.2% had
#500 RNA-copies/ml and 38.4% undetectable viraemia (#50
RNA-copies/ml).
Comparison among transferred and non-transferred patients by
December 2011 revealed that transferred patients had a worst
immunological-virological profile comparing to the non-trans-
ferred group. A lower number of transferred patients were
categorized in clinical status A (23.2% vs. 37.4%, p,0.05) and
achieved undetectable levels of viraemia (38.4% vs. 64.9%,
p,0.05). T-cell CD4 counts (either $25% or .500 CD4+ T-
cells) were also lower among transferred and a lower number of
transferred were on HAART (84.8% vs. 94.6%, p,0.05). No
statistical differences were found in studied clinical features by
December 2011 between transferred patients with and without
available genotype (Table 2).
ART Experience among Transferred Patients
The transferred cohort started any type of ART with a median
age of 5.6 years (SD 3.5 years) and the median duration of ART
was 11.5 years (SD 4.8 years). Only 3 (2.7%) of the 112 transferred
individuals remained drug naı¨ve at transfer and the rest (97.3%)
were ART experienced. Most (84.8%) were receiving HAART,
9.8% had stopped treatment and 2.7% were receiving combined
therapy at the transfer time according to clinical reports. The most
commonly used HAART combinations in our cohort were
2NRTI+1NNRTI (32.6%) and 2NRTI+1PI (28.4%). The pre-
treated patients presented a long treatment history and had
experienced several different ART combinations; the mean
number of regimens was five, with at least 3 HAART regimens
in 48% of them. The main ART families were NRTI, PI and
NNRTI, 94.6%, 84.8%, and 72.3% respectively (Table 2). Triple
class experience was found in almost two-thirds of patients. Use of
other drug families was scarce and only three transferred patients
had experience with the fusion inhibitor, enfuvirtide and one of
them also had received raltegravir, an integrase inhibitor.
Adherence history was assessed according to clinical charts data
but was not available in all cases.
High Prevalence of HIV-1 Resistant Variants in Pretreated
Transferred Patients
Among the 112 patients transferred before the end of December
2011, only in 63 (56.2%) subjects drug resistance genotypes could
be analyzed. Among them, in 48 (76.2%) cases the pol sequence
had been previously reported by our group [12,13]. In the
remaining 15 patients, six patients had an available plasma
specimen stored in the HIV-1 Spanish Biobank and new HIV-1 pol
sequences were newly generated as previously reported [13].
Other 9 patients presented a genotypic resistance profile derived
from pol sequences obtained from plasma specimens recovered
from clinical routine drug-resistance tests performed in hospitals
where the patients were or had been under follow-up. However,
no fasta format sequences of any profile were available. Clinical
specimens in all 63 genotyped samples were obtained before the
transfer time to adult units: during 1993–1999 (5 genotypes),
2000–2004 (27 genotypes) and 2005–2010 (31 genotypes). The
median age of patients when genotypic data was generated was
14.7 years old (SD 4.4). The 63 patients with available genotypic
data included five genotypes (accession numbers HQ426734,
HQ426806, HQ426860, HQ426867, HQ426893) performed
before treatment was initiated. Out of these five, only 2 patients
remained drug naı¨ve until they were transferred to adult units
while the other 3 received any ART during their follow-up. None
of these sequences harboured TDR mutations.
Among the 63 transferred patients of the Madrid cohort of
HIV-infected children with available pol sequences or resistance
profiles, the prevalence of HIV drug resistance mutations was
analyzed according to the drug class family. Fifty-eight were
pretreated and 5 remained drug-naı¨ve at sampling time. No TDR
mutations were found among the pol sequences from the 5
transferred naı¨ve subjects. The most prevalent DRM found in the
58 transferred ART-experienced patients were: for PI, L90M
(27.5%), V82A (15.7%), M46I (13.7%) and D30N (9.8%); for
NRTI, M41L (48.1%), D67N (40.4%), T215Y (40.4%), L210W
(34.6%), M184V (25%), T69D (23.1%), and K219Q (23.1%); and
for NNRTI, K103N (19.2%), Y181C (7.7%) and G190A (7.7%).
Global resistance prevalence among the 58 transferred ARV-
exposed pretreated patients with available pol sequences or
resistance profiles was 50.9% for PI, 76.9% for NRTI and
36.5% for NNRTI (Table 3). No primary drug resistance
mutations were found among naı¨ve subjects. According to our
data, no statistical differences were found between the resistance
rate and the duration of treatment (data not shown).
Higher Prevalence of Drug Resistance Mutations Among
Transferred Patients than in Non-transferred
Besides assessing the global prevalence of DRM in the 58
pretreated patients of the transferred cohort, prevalence of DRM
was also compared to the non-transferred cohort. The first
included the 58 transferred and pretreated patients with available
genotypic data compared to the 131 non-transferred pretreated
pediatric patients from the Madrid cohort of HIV-1 infected
children (Table 3). All 131 non-transferred pediatric patients had
available resistance genotype, previously reported [12,13] and
with available GenBank accession numbers.
Transferred patients tended to present higher DRM prevalence
when compared to non-transferred children (Table 3). Drug
resistance mutations were found in a higher number of transferred
patients than in the non-transferred pretreated population under
follow up in Madrid for PI (50.9% vs. 36.8%, p = NS) and for
NRTI, 76.9% vs. 62.1%, p = NS) and lower for NNRTI (36.5% vs.
40.5%, p = NS). However, resistance prevalence was significantly
higher among transferred patients for the PI+NRTI combination
(19% vs. 8.4%, p,0.05). Triple resistance was similar to non-
transferred pediatric patients (17.3% vs. 17.6%, p = NS).
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Table 2. Characteristics of the non-transferred, transferred and transferred with available genotypic profile patients by December
2011.
Features Non-transferred n=131 Transferred n=112 Transferred with genotype* n=63
Mean age (years) 14.7 18.9 18.5
LTNP [n (%)] 1 (0.8) 5 (4.5) 2 (3.2)
Median ART duration [years (SD)] 12 (4.5) 11.5 (4.8) 13.5 (4.1)
Median follow-up [years SD)] 13.2 (5.2) 15.6 (4.5) 16.7 (3.6)
Immunological status [n (%)]
1 8 (6.1) 4 (3.6) 2 (3.2)
2 41 (31.3) 31 (27.7) 18 (28.5)
3 79 (60.3) 75 (66.9) 43 (68.3)
Unknown 3 (2.3) 2 (1.8) -
Clinical status [n (%)]
N - 2 (1.8) 1 (1.6)
A** 49 (37.4) 26 (23.2) 14 (22.2)
B** 35 (26.7) 45 (40.2) 23 (36.5)
C 43 (32.8) 39 (34.8) 25 (39.7)
Unknown 4 (3.1) - -
CD4 count (%) [n (%)]
,15% 3 (2.3) 6 (5.4) 3 (4.8)
15–24% 18 (13.7) 26 (23.2) 15 (23.8)
$25%** 105 (80.2) 74 (66) 43 (68.2)
Unknown 5 (3.8) 6 (5.4) 2 (3.2)
CD4 count (cells/ml) [n (%)]
Mean 770.5 cells/ml Mean 627.5 cells/ml Mean 654 cells/ml
#200 3 (2.3) 4 (3.6) 1 (1.6)
201–350 6 (4.6) 7 (6.3) 5 (7.9)
351–500 13 (9.9) 10 (8.9) 4 (6.4)
.500** 99 (75.6) 62 (55.3) 36 (57.1)
Unknown 10 (7.6) 29 (25.9) 17 (27)
Viral load (HIV-1 RNA-copies/ml) [n (%)]
#20** 41 (31.3) 12 (10.7) 9 (14.2)
21–50 44 (33.6) 31 (27.7) 23 (36.5)
51–200 10 (7.6) 10 (8.9) 4 (6.4)
201–500 7 (5.3) 10 (8.9) 2 (3.2)
501–1,000 - 4 (3.6) 3 (4.8)
1,001–10,000 12 (9.2) 19 (17) 9 (14.3)
.10,000 13 (9.9) 16 (14.3) 11 (17.4)
Unknown 4 (3.1) 10 (8.9) 2 (3.2)
ART experience [n (%)]
Drug naive 1 (0.8) 3 (2.7) 2 (3.2)
PI-experienced 116 (88.6) 95 (84.8) 54 (85.7)
NRTI-experienced** 130 (99.2) 106 (94.6) 59 (93.6)
NNRTI-experienced 99 (75.6) 81 (72.3) 47 (74.6)
FI-experienced - 3 (2.7) 1 (1.6)
InI-experienced - 1 (0.9) 1 (1.6)
PI+NRTI+NNRTI-experienced 88 (67.2) 72 (64.3) 42 (66.7)
Treatment status [n (%)]
HAART** 124 (94.6) 95 (84.8) 54 (85.7)
Stopped-treatment 3 (2.3) 11 (9.8) 6 (9.5)
Naive 1 (0.8) 3 (2.7) 2 (3.2)
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Higher Predicted Level of Resistance to PI and NRTI
among Transferred Patients
Figure 1 shows the comparison of the predicted level of
resistance to each drug in all pretreated patients from the two
study cohorts. Analysis of the genotypic resistance interpretation
revealed that transferred adolescents presented a significantly
higher predicted level of resistance to all drugs from the PI and
NRTI families probably explained by the long-term therapy
history of these patients. Half of the transferred patients carried
infecting HIV-1 variants resistant to NFV, followed by AZT and
d4T (nearly 40% of them). Similar predicted resistance was
observed for 3TC and FTC in the non-transferred and transferred
study groups (around 20%). Between nearly 20% and 30% of the
adolescents in Madrid were infected with variants resistant to the
remaining PI drugs, except for TPV/r and DRV/r, the new PI
drug generation. EFV and NVP were the NNRTI with the most
compromised susceptibility in both cohorts (around 20–30%),
being higher in non-transferred patients. Data revealed a low (2–
5%) predicted resistance level to etravirine and rilpivirine, the new
NNRTI drugs; resistance levels to these drugs remained low in a
gap between 2% and 5% for both studied cohorts.
Low Prevalence of HIV-1 Non-B Variants in Transferred
Patients
Most (98.1%) of the transferred patients were infected by
subtype B, the most prevalent HIV-1 variant in North America
and Western Europe, including Spain [13,21]. Only one
transferred perinatally infected female carried a ‘‘pure’’ sub-
subtype A2. She was a white-Caucasian, vertically infected and
born of Spanish parents in 1992. Prevalence of HIV-1 non-B
variants among the 54 transferred patients with available pol
sequence was low (1.9%, 1/54), compared to the 11.5% (15
patients) found among the 131 non-transferred children of the
same pediatric cohort (Table 1) or the 12.2% reported n the
Spanish cohort of antiretroviral treatment-naı¨ve HIV-infected
patients [21]. Of interest, recombinant viruses were absent in
transferred patients although found in 60% (9/15) of infections
caused by non-B variants in the non-transferred pediatric cohort,
respectively.
Sequence Data
Pol (PR and/or RT) sequences from 48 (88.8%) of the 54
transferred patients included in this study had been previously
submitted to GenBank [13]: HQ426715, HQ426719, HQ426725,
HQ426728, HQ426734, HQ426766, HQ426768, HQ426779,
HQ426780, HQ426788, HQ426799, HQ426806, HQ426807,
HQ426818, HQ426826, HQ426840, HQ426842, HQ426847,
Table 3. Comparison of HIV drug resistance mutations prevalence according to drug class family in the non-transferred and the
transferred pediatric cohorts.
Transferred patientsa (n=58) Non-transferred childrenb (n=131)
Patients with available PR 51 125
Patients with available RT 52 116
Prevalence of drug resistance mutations (%) [95% CI]c
Global (to any class) 81.0 [70.1–92] 69.5 [61.2–77.7]
To PIs 50.9 [36.3–65.7] 36.8 [27.9–45.7]
To NRTIs 76.9 [64.5–89.3] 62.1 [52.8–71.3]
To NNRTIs 36.5 [22.5–50.6] 40.5 [31.2–49.9]
To NRTI+NNRTI 12.1 [2.8–21.3] 12.2 [6.2–18.2]
To PI+NRTI** 19 [8–29.9] 8.4 [3.3–13.5]
To PI+NNRTI – 0.8 [0.02–4.2]
To PI+NRTI+NNRTI 17.3 [6.7–27.8] 17.6 [10.7–24.5]
aSelected patients from the Madrid cohort of HIV-1 infected children that have been transferred to adult units by December 2011.
bPretreated patients selected from the Madrid cohort of HIV-1 infected children excluding those transferred to adult units.
cPrevalence of drug resistance mutations was determined following the IAS-USA 2011 list [18]. PR, protease; RT, reverse transcriptase; NRTI, nucleoside reverse
transcriptase inhibitors; NNRTI, non-NRTI; PI, protease inhibitors.
**Statistical difference (p,0.05) has been found between transferred and non-transferred patients for this feature.
doi:10.1371/journal.pone.0052155.t003
Table 2. Cont.
Features Non-transferred n=131 Transferred n=112 Transferred with genotype* n=63
Monotherapy 1 (0.8)
Combined 2 (1.5) 3 (2.7) 1 (1.6)
SD, standard deviation; ART, antiretroviral therapy; PI, protease inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-NRTI; FI, fusion inhibitors, InI;
integrase inhibitors.
*Transferred to adult units with available resistance genotyping profile.
**Statistical differences (p,0.05) have been found between transferred and non-transferred patients for these features.
doi:10.1371/journal.pone.0052155.t002
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HQ426850, HQ426857, HQ426860, HQ426861, HQ426866,
HQ426867, HQ426868, HQ426869, HQ426874, HQ426879,
HQ426880, HQ426883, HQ426889, HQ426890, and
HQ426893. In reference [12]: JQ351951, JQ351960,
JQ351984, JQ351986, JQ351988, JQ351989, JQ351995,
JQ351997, JQ352005, JQ352006, JQ352010-JQ352012,
JQ352014, and JQ352021. The 6 newly generated pol sequences
for this study were submitted to GenBank with the following
accession numbers: JQ828989-JQ828994. GenBank accession
numbers for the 131 sequences from non-transferred children were
previously reported [12,13].
Discussion
Due to the low number of new cases of HIV infection caused by
MTCT in developed countries [2], perinatally infected cohorts will
tend to reduce. However, several studies have assessed the current
state of adolescent survivors of perinatally or early acquired HIV
infection [22–33]. As ART becomes more widely available in the
developing world, increasing the effective viral suppression with
immunologic reconstitution, we can expect a steady increase in the
number of children being transferred into adult units, as reported
in European [24–26] and North American pediatric [22,29,32]
cohorts. This recent process described in high income regions
could eventually occur in developing countries, if the access to
optimal treatment is maintained.
High Rate of Perinatally HIV-1 Infected Patients
Transferred to Adults Units in Madrid
Features of the transferred patients from the Madrid cohort of
HIV-1 infected children have been scarcely studied [34]. Among
the 534 patients from the Madrid cohort of HIV-1 infected
children by the end of December 2011, a total of 112 (21%) had
reached adolescence and were transferred to adult units from 1997
through 2011. The first patient was transferred in 1997. The high
percentage of transferred patients, even higher than in the British
pediatric HIV CHIPS cohort [23] (n = 103; 16% vs. n = 112;
21%), is directly related to the high number of HIV-1 infections
occurring in Spain in the early nineties due to the so called ‘‘heroin
epidemic’’. The abuse of heroin during the 1980s and 1990s in
Spain had a special impact in women, reaching the highest AIDS
incidence and prevalence in Western Europe, which led to a high
incidence of MTCT in children born between 1980 and 1990
[11,35]. Future transitioning programs will include a smaller
number of patients due to the low number of new diagnoses [2,9]
of HIV-1 among children in high income countries.
Higher Prevalence of Drug Resistant Strains among
Transferred and Non-transferred Patients
The emergence of drug resistance due to incomplete viral
suppression and incomplete adherence are the major obstacle for
an effective ART [36]. Adolescents with perinatally acquired HIV
are heavily pretreated, have a long history of treatment with many
regimen switches, and present variable levels of adherence to the
treatment, mainly during adolescence. However, there are few
data about disease progression, response to ART and drug
resistance prevalence in vertically HIV-infected adolescents in the
era of effective therapy, even though their number is increasing in
developed countries where ARV therapy is guaranteed. The
results presented showed that two thirds of transferred patients
from the Madrid cohort of HIV-1 infected children to adult units
were triple class-experienced, higher than in other cohorts as in the
UK (64.3% vs. 47%, respectively) [23]. Results may be explained
by longer exposure to older, less efficacious treatments. In fact,
HIV infected patients during childhood in our cohort were mainly
infected during the early 1990’s, and had to face the monotherapy
and dual therapy regimens available at the time, thus increasing
the risk of virological failures due to resistance development. The
first patient reached adulthood in 1997 and thus had received
previous, less efficacious treatments during his childhood.
Interestingly, DRM prevalence to all 3 drug classes among
transferred patients was higher than for non-transferred infected
children. This fact could be caused by regimen switches due to
Figure 1. Predicted resistance level to antiretroviral drugs in pretreated patients from the two studied cohorts. Resistance level was
estimated according to the HIVdb Interpretation Algorithm (Stanford University, Palo Alto, CA, USA) [19]. PI, protease inhibitors: nelfinavir (NFV),
saquinavir/r (SQV/r), indinavir/r (IDV/r), atazanavir/r (ATV/r), fosamprenavir/r (FPV/r), lopinavir/r (LPV/r), tipranavir/r (TPV/r) and darunavir/r (DRV/r),
where ‘‘/r’’ indicates co-administration with low-dose ritonavir (RTV) for pharmacological ‘‘boosting’’. NRTI, nucleoside reverse transcriptase inhibitors:
zidovudine (AZT), stavudine (d4T), lamivudine (3TC), emtricitabine (FTC), didanosine (DDI), abacavir (ABC), tenofovir (TDF). NNRTI, non-nucleoside
reverse transcriptase inhibitors: efavirenz (EFV), nevirapine (NVP), rilpivirine (RPV), etravirine (ETR). **Statistical differences (p,0.05) in resistance levels
have been found between transferred and non-transferred patients for these drugs.
doi:10.1371/journal.pone.0052155.g001
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therapeutic failure or because of the availability of new drugs
during the infection period. As a consequence of their long
treatment history and the treatment switches they have experi-
mented, 81% of the patients transferred to adult units harboured
resistant virus to at least one of the drug classes, higher than in
non-transferred children (69.5%) mainly for NRTI, the first
available drug class for clinical use, and for PI. This high rate of
resistance could have compromised the susceptibility found in our
data from both the PI and NRTI families.
In fact, the pediatric population (transferred and non-trans-
ferred) infected by viruses carrying triple resistance mutations was
significantly higher than in pretreated adults from Madrid (17% vs.
8.6%), and moreover, was higher than in adolescents from the UK
and Ireland (12%) [23] and the COHERE pediatric cohort of
perinatally infected children in Western Europe aged less than 16
years (10%) [37]. On the other hand, DRM to NNRTI was
slightly higher in the Madrid cohort of HIV-1 infected children
than in the transferred group, so reflecting their preferential use in
the pediatric population during the study period. These results on
prevalence highlight the potential problem that clinicians have and
will face in the near future with HIV-1 adolescents who are highly
resistant to all drug classes.
Possible Candidates to Rescue Transferred Highly
Pretreated Patients
Treatment failure in children during ART is frequent, develops
fast and with more extensive drug resistance than in adults, leading
to detectable viral loads and immunological damage [37–42].
Thus, keeping a close surveillance of adherence has to be a priority
in these heavily pretreated adolescents requiring treatment for life
[42,43]. Moreover resistance studies are also required to optimize
ARV regimens. According to the predicted drug susceptibility, our
data revealed than TDF (NRTI) and the new PI (TPV/r and
DRV/r) and NNRTI (ETR and RPV) drugs could be good
alternatives for inclusion in future ARV regimens to control the
viraemia in highly pretreated transferred adolescents in Madrid.
Adolescents could also benefit from the newly licensed drugs to
treat HIV-1 infection for adults. Other drug families (cell-entry
and integrase inhibitors), could be good candidates to control
viraemia among pretreated transferred patients in Madrid due to
their previous scarce exposure (,1%). However, the presence of
X4-tropic variants in over 80% of the cohort of antiretroviral-
experienced children and adolescents with vertical HIV-1
infection in Madrid has recently been reported [44]. The authors
indicate a very limited role for CCR5 antagonists as part of salvage
regimens for highly treatment-experienced vertically infected
patients with extensive antiretroviral drug resistance [44]. Thus,
integrase inhibitors could be the best rescue alternative in the cases
of therapeutic failure with multiresistance, although additional
genetic resistance studies should be performed to guarantee their
usefulness.
Low Prevalence of HIV-1 Non-B Variants Infection among
Transferred Patients
Epidemiological differences related to the nature of HIV-1
infecting variants were found between the non-transferred cohort
of HIV infected children (11.4%) and with those transferred to
adult units (1.9%). Pediatric patients that reached adulthood and
were transferred to adult units were mainly infected by subtype B
(98.2%). This fact is explained by the long term infection of our
patients (mean age of 18.9 years), reflecting the local epidemio-
logical situation in Spain at the time in which circulating variants
other than B had not yet been detected in Spain.
Previous studies in the Madrid cohort of HIV-1 infected
children and adolescents reported a non-B prevalence of 10%
[12,13]. In fact, in Madrid an increase of HIV-1 non-B infections
after year 2000 was reported among infected children [12] and
among newly HIV infected adults [14]. Interestingly, the
increasing complexity of the epidemic reported in HIV-infected
adults [21,45] and in the pediatric population in Madrid [13] was
not observed among the transferred population, in whom no
recombinant strains were found. As a limitation, only half (n = 54)
of the transferred cohort had an available pol sequence to perform
HIV-1 variant characterization. Prevalence of HIV-1 non-B
variants infecting children and adults from Madrid has been
estimated as about 10% [12,13,21]. Similar results have been
published for other pediatric cohorts, where non-B infections
ranged from 5 to 15% [46,47].
Conclusions
Understanding the progress of HIV-1 infected children through
pediatric care until they reach adolescence in developed countries
could help to improve and plan adequate clinical and psycholog-
ical transitioning services for the HIV-1 infected children that will
reach adolescence [23,24,26,33] in the future. The increasing
resistance prevalence among the HIV-infected-pediatric popula-
tion in Spain highlights the importance of specific drug-resistance
and drug-susceptibility surveillance in long-term pretreated
children to optimize treatment regimens. Clinicians in Spain
should consider that young adults infected during childhood do
not present same clinical features as those young adults infected by
other routes and that they require a specific clinical follow up.
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